Clinical Trials Logo
  1. Home
  2. Lung Transplant Rejection
  3. NCT03967340

PREdiction of Chronic LUng Allograft Dysfunction — PRELUD  

Lung Transplant Rejection Clinical Trial

Official title:
PREdiction of Chronic LUng Allograft Dysfunction

Clinical Trial Summary

Chronic lung allograft dysfunction (CLAD) is the leading cause of long-term mortality after lung transplantation. Several risk factors for CLAD have been identified, but the exact pathophysiology and triggering molecular factors remain largely unknown. Moreover, in clinical practice, no integration of the different risk factors is achieved. CLAD is therefore diagnosed most often late with the persistent decline in respiratory function, revealing a profound and irreversible alteration of the pulmonary graft. Several blood biomarkers that can predict the occurrence of CLAD more than 6 months before clinical diagnosis have been identified and validated. From these preliminary results, a composite score is being developed from independent samples from the COLT (COhort in Lung Transplantation) cohort. The main objective of this project is to validate this robust and predictive composite score (biological and clinical) of CLAD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03967340
Study type Observational
Source Nantes University Hospital
Contact
Status Active, not recruiting
Phase
Start date September 10, 2020
Completion date October 2024
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06309628 - Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
Withdrawn NCT02893176 - Macitentan in the Treatment of Organ Rejection After Lung Transplantation Phase 4
Completed NCT02441413 - Transplant Optimization Using Functional Imaging (TROFI) N/A
Recruiting NCT05375149 - Exhaled Breath Particles in Lung Transplantation
Active, not recruiting NCT05260372 - Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
Recruiting NCT06082037 - A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction Phase 3
Recruiting NCT04714801 - Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation Phase 1/Phase 2
Active, not recruiting NCT05170425 - LAMBDA 002 (Lung Registry) Study
Completed NCT02474927 - Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Phase 2
Recruiting NCT05006742 - Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients N/A
Recruiting NCT02812290 - Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
Not yet recruiting NCT03500575 - Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients N/A
Withdrawn NCT03805178 - Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization Phase 2
Completed NCT03359863 - Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction Phase 2
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3
Completed NCT01985412 - Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
Completed NCT04234919 - Longitudinal Study of Cell Free DNA in Lung Transplant
Recruiting NCT04837339 - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation N/A
Recruiting NCT03090581 - Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation. N/A
Recruiting NCT06112951 - A Prospective Randomized Trial of ECP in Subclinical AMR N/A